![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Tepkinly (epcoritamab) is an IgG1-bispecific antibody, which is approved for the treatment of relapsed/refractory follicular lymphoma. It is designed to direct cytotoxic T cells selectively.
Lead Product(s): Epcoritamab
Therapeutic Area: Oncology Product Name: Tepkinly
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: AbbVie Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 28, 2024
Details:
Epkinly (epcoritamab) is an IgG1-bispecific antibody, which is approved for the treatment of relapsed/refractory follicular lymphoma. It is designed to direct cytotoxic T cells selectively.
Lead Product(s): Epcoritamab
Therapeutic Area: Oncology Product Name: Epkinly
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: AbbVie Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 26, 2024
Details:
Epkinly (epcoritamab) is an IgG1-bispecific antibody, which is approved for the treatment of relapsed/refractory follicular lymphoma. It is designed to direct cytotoxic T cells selectively.
Lead Product(s): Epcoritamab
Therapeutic Area: Oncology Product Name: Epkinly
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: AbbVie Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 02, 2024
Details:
GEN1046/BNT311 (acasunlimab), an investigational bispecific antibody (PD-L1x4-1BB), as monotherapy and in combination with pembrolizumab in patients with PDL(1)-positive mNSCLC.
Lead Product(s): Acasunlimab,Pembrolizumab
Therapeutic Area: Oncology Product Name: GEN1046
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: BioNTech
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2024
Details:
The acquisition gives Genmab worldwide rights to three candidates in clinical development, including Rina-S (rinatabart sesutecan), which is an FRα-targeted ADC being developed as a novel treatment option for patients with ovarian and endometrial cancer.
Lead Product(s): Rinatabart Sesutecan
Therapeutic Area: Oncology Product Name: Rina-S
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Recipient: ProfoundBio
Deal Size: $1,800.0 million Upfront Cash: $1,800.0 million
Deal Type: Acquisition May 21, 2024
Details:
Tivdak (tisotumab vedotin) is an antibody-drug conjugate that acts as coagulation factor III binding agent & tubulin inhibitor. It is approved for the treatment of recurrent or metastatic cervical cancer.
Lead Product(s): Tisotumab Vedotin
Therapeutic Area: Oncology Product Name: Tivdak
Highest Development Status: ApprovedProduct Type: Large molecule
Recipient: Pfizer Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 29, 2024
Details:
Through the Acquisition, Genmab will leverage the worldwide rights of three candidates in clinical development, including PRO1184 (rinatabart sesutecan) for the treatment of FRα-expressing platinum-resistant ovarian cancer.
Lead Product(s): Rinatabart Sesutecan
Therapeutic Area: Oncology Product Name: PRO1184
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Recipient: ProfoundBio
Deal Size: $1,800.0 million Upfront Cash: $1,800.0 million
Deal Type: Acquisition April 03, 2024
Details:
Epkinly (epcoritamab) is an IgG1-bispecific antibody, being evaluated to-treat relapsed/refractory follicular lymphoma, which is designed to direct cytotoxic T cells selectively to elicit an immune response towards target cell types.
Lead Product(s): Epcoritamab
Therapeutic Area: Oncology Product Name: Epkinly
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: AbbVie Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 26, 2024
Details:
Tivdak (tisotumab vedotin-tftv) is a tissue factor (TF)-directed antibody drug conjugate. It is approved by USFDA for the treatment of cervical cancer.
Lead Product(s): Tisotumab Vedotin
Therapeutic Area: Oncology Product Name: Tivdak
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Pfizer Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 02, 2024
Details:
Tivdak (tisotumab vedotin-tftv) is an antibody-drug conjugate (ADC) composed of Genmab’s human monoclonal antibody directed to tissue factor (TF) and Pfizer’s ADC technology. It is being evaluated in phase 3 studies for the treatment of recurrent or metastatic cervical cancer.
Lead Product(s): Tisotumab Vedotin
Therapeutic Area: Oncology Product Name: Tivdak
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Pfizer Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 09, 2024